OMEGA-3 FATTY-ACID ENRICHED PARENTERAL NUTRITION REGIMENS IN HOSPITALIZED PATIENTS IN EU5 COUNTRIES: A PHARMACOL CO NOM 1C ANALYSIS
L Pradelli5 . K. Mayer*. S. Klek\ A. J. Omar Alsaleh1. M. Rosenthal'. A R Heller^. M. Muscaritoli7. 'Adre.s. Torino. Italy: JUmvrnaty Giessen. Giessen Germany: Hanley Dudricks Memorial Hospital Skamna. Poland: 'Via Vittorio Aifieri 17. AdRcs. Torino. Italy. ’’Di vision of Trauma and Acute Care Surgery, University of Florida College of Medicine. Mi am. United States. bAnaesthesiology and Intensive Care Medicine. University of Augsburg. Augsburg, Germany:' Translational and Precision Medicine. Sapienza University of Rome. Rome. Italy
- Corresponding author.
Vitamin D and Omega-3 category starts with
"Omega-3 Fatty Acids in Modern Parenteral Nutrition: A Review of the Current Evidence" 2016
- Omega-3 reduced pancreas transplant failure by 3X and sepsis by 2X – review Dec 2019
- Hospitalization costs reduced ~3,000 dollars when intravenous nutrition was augmented with Omega-3 – Aug 2019
- Omega-3 supplements taken before and after surgery actually helped – RCT Nov 2018
- ICU length of stay reduced when supplement with Omega-3 – meta-analysis July 2018
- 3 days of Omega-3 before cardiac surgery reduced risk of post-op bleeding by half – RCT March 2018
- Omega-3 benefits in surgery and ICU including via IV - March 2016
- Omega-3 reduced time in hospital and atrial fibrillation after cardiac surgery – meta-analysis May 2016
- 2.7 fewer days in hospital after surgery if had taken Omega-3 (19 RCT) – meta-analysis – June 2017
- Sepsis: 4 fewer days in ICU if add Omega-3 – meta-analysis of 12 RCT – June 2017
- Cognitive decline after traumatic brain injury reduced by Omega-3 (mice) – Nov 2016
- Football Brain injuries prevented by Omega-3 – RCT Jan 2016
- Omega-3 should be cost-effective to reduce days in ICU – simulation June 2015
Rationale The aim of this study is to perform a cost-consequence analysis of the use of omega-3 (o>-3) fatty-acid enriched parenteral nutrition (PN) in the EUS countries, from the hospital perspective.
Methods: A cost-consequence analysis was performed using a probabilistic discrete event simulation model with country-specific inputs derived from published sources. The relative o>-3 supplementation effect estimates were from our recent meta-analysis 11). The model estimates and compares costs and clinical impact associated with <*-3 fatty-acid enriched PN vs. PN containing standard lipid emulsions (without omega-3 fatty acids; std-PN).
Data captured were
- cost of PN.
- cost of infection.
- cost of hospital length of stay and
- total cost per patient;
- clinical events were infections avoided and hospital length of stay.
Inputs uncertainty is evaluated via both deterministic (DSA) and probabilistic (PSA) sensitivity analyses.
Results: Avoided infections and shortened length of stay due to to-3 fatty-acid enriched PN. as compared with std-PN. in the EU5s haw an expected impact on total costs per patient as shown in Table I. Both the PSA and DSA analyses confirmed the robustness of the outputs of the model to all tested changes in the inputs.
Table 1 Reduced costs
Conclusion: u>-3 fatty-acid enriched PN is likely a dominant alternative to std-PN from the point of view of a hospital in any of the EUS countries as it is associated with significantly improved patient outcomes and cost savings.
|638 visitors, last modified 20 Aug, 2019,